Publications by authors named "P Kaesberg"
Mastocytosis is a heterogeneous group of disorders comprising cutaneous mastocytosis, systemic mastocytosis, and mast cell sarcoma. It is associated with a variety of symptoms related to the release of mast cell mediators and mast cell tissue infiltration. Referral to specialized centers with expertise in the management of mastocytosis and multidisciplinary collaboration with subspecialists (eg, allergists for the management of anaphylaxis and drug hypersensitivities, anesthesiologists for invasive procedures or surgery, high-risk obstetrician for pregnancy) is recommended.
View Article and Find Full Text PDFArticle Synopsis
- Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different forms of the same disease, with similar treatment approaches.
- Prognostic factors such as undetectable minimal residual disease after treatment can significantly predict better survival outcomes for patients.
- Treatment decisions depend on disease characteristics, genetic mutations, age, overall health, and the side effects of the treatments, as detailed in the NCCN Guidelines.
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
September 2022
The classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for the management of MPN in adults. The Guidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia.
View Article and Find Full Text PDFBackground: Hyper-CVAD is an established regimen for adult ALL that was developed at the MD Anderson Cancer Center (MDACC). However, results can vary across different institutions given the heterogeneity of patient populations and institutional practices. Moreover, while a MDACC study demonstrated that the combination of ponatinib plus hyper-CVAD produced remarkable activity in untreated Ph+ ALL, it remains to be externally validated.
View Article and Find Full Text PDFArticle Synopsis
- The treatment options for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have improved, especially with the introduction of targeted therapies like BTK and BCL-2 inhibitors.
- These therapies offer a chemotherapy-free alternative for patients who are newly diagnosed or have relapsed/refractory disease.
- Research indicates that having undetectable minimal residual disease post-treatment is a key indicator of better survival rates, prompting updates to the NCCN Guidelines on treatment recommendations.